Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy

Clin Colorectal Cancer. 2024 Mar;23(1):1-3. doi: 10.1016/j.clcc.2023.10.005. Epub 2023 Oct 14.

Authors

Jacopo Giuliani¹, Beatrice Mantoan², Daniela Mangiola³, Marco Muraro³, Giuseppe Napoli³, Marina Tommasi⁴, Francesco Fiorica³, Marta Mandarà³

Affiliations

¹ Department of Oncology, Azienda ULSS 9 Scaligera, Legnago (VR), Italy. Electronic address: [email protected].
² Department of Diagnostic Imaging, Azienda ULSS 9 Scaligera, Legnago (VR), Italy.
³ Department of Oncology, Azienda ULSS 9 Scaligera, Legnago (VR), Italy.
⁴ Pharmaceuthical Department, Azienda ULSS 9 Scaligera, Legnago (VR), Italy.

PMID: 37932152
DOI: 10.1016/j.clcc.2023.10.005

No abstract available

Keywords: Bevacizumab; Cost of drugs; Metastatic colorectal cancer; Third-line; Trifluridine/tipiracil.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab / therapeutic use
Colonic Neoplasms*
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / pathology
Cost-Benefit Analysis
Drug Combinations
Humans
Pyrrolidines*
Rectal Neoplasms*
Thymine*
Trifluridine / therapeutic use
Uracil / therapeutic use

Substances

tipiracil
Bevacizumab
Trifluridine
Drug Combinations
Uracil
Pyrrolidines
Thymine